Abstract: Inhibition of calcium-independent myocardial phospholipase A.sub.2 is shown for compounds of the formula: ##STR1## wherein R and R.sup.1 independently represent hydrogen and halogen, alkyl, alkenyl and alkynyl radicals; R.sup.2 represents aryl, aryloxy, and heteroaryl radicals; and X is 1 or 2.

Abstract: This invention provides a recipe for making a detoxification medicine named DTS (Deities) for curing drug addiction. This DTS (Deities) medicine comprises no narcotic but mainly is made up by several kinds of effective ingredients of biological substances refined from various natural herbs and bioproducts. Drug addicts can be weaned and cured safely from addiction induced by Heroin, Cocaine, Morphine, Amphetamines, Hemp or Opium, and other substances within 7-30 days, by means of DTS (Deities) which can get rid of drug poisons present in an addict's blood and marrow. Further, DTS (Deities) can also be used to clear away tobacco tar and nicotine deposits so that it serves to wean from cigarette smoking as well.

Abstract: The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.

Abstract: The invention relates to pharmaceutical compositions for neuroprotection containing arylcyclohexylamines. These compositions comprise an arylcyclohexylamine in accordance with the formulas: ##STR1## in which: R.sup.1 represents ##STR2## with R.sup.4 being a hydrogen atom, a fluorine atom, an iodine atom or a methyl radical, R.sup.2 stands for a hydrogen atom, the radical OH or the radical CH.sub.3 and R.sup.3 stands for hydrogen atom or the radical CH.sub.2 R.sup.5 with R.sup.5 representing H, OH, Cl, Br or CH.sub.3 COO, provided that R.sup.2 and R.sup.3 are not both a hydrogen atom, or an addition salt to a pharmaceutically acceptable acid of said arylcyclohexylamine.

Abstract: Treatment of apnea and/or bradycardia employing 5-ethyldihrdo-5-phenyl-4,6-[1H,5H]-pyrimidenedione (primidone).

Abstract: The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.

Abstract: Enol form .delta.-lactone of diketogulonic acid (2,3,6-trihydroxy-4-oxo-2-hexen-5-olide; R-345), which is the enediol type oxidation product of ascorbic acid, and/or its sodium salt, potassium salt or calcium salt has activities of markedly reducing the toxicity of Adriamycin, reducing radiation injury, reducing liver damage induced by an organic halogen compound, and further accelerating recovery from a high blood sugar level in Alloxan-induced diabetes, using vitanim E in combination.

Abstract: A method for the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischaemic events, in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of a 5-HT1.sub.A agonist.

Abstract: A preserved composition suitable for topical application to mammalian skin or hair for inducing, maintaining or increasing hair growth comprises:(i) a special ester of pyroglutamic acid; and(ii) a cosmetically acceptable vehicle for the ester.

Abstract: A pharmaceutical solid preparation of active form of vitamin D.sub.3 of improved stability which comprises a composition of active form of vitamin D.sub.3 dispersed in an excipient readily soluble in organic solvent and a basic substance.As a basic substance, are cited sodium citrate, magnesium oxide or the like.

Abstract: A method is provided for lowering serum cholesterol and thereby inhibiting fatty streak lesions of atherosclerosis by administering to a patient a phosphorus-containing ACE inhibitor, such as fosinopril or ceronapril, alone or in combination with a cholesterol lowering drug, such as pravastatin.

Abstract: This invention pertains to an improved method of inhibiting peroxide-reduction catalytic activity and concomitant toxicity of asbestos and nonasbestos iron-containing silicates. These undesirable reactions can be substantially reduced or essentially eliminated by contacting these potentially harmful materials with an aqueous solution comprising a non-mutagenic non-toxic iron chelating agent, such as phytic acid, diethylenetriamine pentaacetic acid (DTPA) or derivatives of these.

Abstract: Compositions and methods for increasing the contractility of the mammalian heart as shown by a positive inotropic effect are disclosed, employing protoberberine alkaloids such as berberine, discretine, xylopinine, berrberubine, tetrahydropalmatine, and stepharotine in combination with cardiac glycosides such as ouabain, digoxin, digitoxin, deslanoside and digitalis.

Abstract: 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl)propyl]-amino]-1,3-dimethyluracil can be used as a therapeutic agent for urinary obstruction.

Abstract: According to the invention there is provided various methods of treating mammalian interstitial cystitis and/or urethral syndrome through the use of Nifedipine, a calcium channel antagonist which has been primarily used for the treatment of coronary artery spasms and hypertension. Specifically, the invention is directed to the adminstration of an therapeutically effective amount of Nifedipine to mammals suffering from interstitial cystitis and/or urethral syndrome. The Nifedipine may be administered in admixture with a pharmaceutically acceptable carrier in a unit dosage form. The route of administration is that deemed preferred by the attending physician, with oral administration being preferred.

Abstract: The rate and character of mammalian hair growth is altered by topical application to the skin of a composition containing an inhibitor of the enzyme transglutaminase.

Abstract: In a process for the elimination of germs, especially the removal of algae from water by means of water soluble quaternary ammonium compositions a polymeric salt of formula (I) ##STR1## wherein R is a C.sub.1 -C.sub.7 hydrocarbon group,m and n are a number of from 4 to 12 regardless of each other,x is a number of from 10 to 300, andhal is chlorine, bromine, or iodineis added to the water as the quaternary ammonium composition in an amount of more than 0.1 ppm and the process is carried out in the absence of heavy metal ions.

Abstract: A novel composition and/or method for the treatment of alcoholism, wherein the composition comprises a therapeutically effective dosage of disulfiram and a drug that affects the neurological system in a manner similar to alcohol, preferably a habit-forming or addictive drug. The method comprises administering a composition to alcoholics that combines therapeutically effective dosages of disulfiram and a habit-forming or addictive drug into a single composition. Preferably, the habit-forming or addictive medication is an anti-anxiety drug and is a member of the benzodiazepine family. Most preferably, the habit-forming, anti-anxiety drug is diazepam.

Abstract: Disclosed are methods employing compositions composed of unique mixtures of phospholipids and neutral lipids to treat the luminal lining of the gastrointestinal tract in the prevention or treatment of ulcerogenic processes such as peptic ulcer disease and inflammatory bowel disease. Compositions including mixtures of saturated or unsaturated phospholipids, together with saturated or unsaturated triglycerides and/or sterols, are shown to provide a surprising ulcer protective efficacy in experimental models. Further enhancement of activity is found upon the addition of a polyvalent cation or antioxidant to the various lipid mixtures.The present invention also discloses unique methods employing mixtures of phospholipids and neutral lipids for surfactant replacement therapy in the treatment of the various forms of respiratory distress syndrome. These compositions are shown to greatly enhance the surfactant replacement efficiency of surface-active lipids.

Abstract: Method of treatment of affections related to a disturbance of the intra and extra cellular movements of calcium at the cerebral level, which comprises administering an aromatic aminoalkoxy derivative of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which A represents a chain having any of the following structures: ##STR2## Ar represents a group of structure: ##STR3## n takes the value 1 or 2 when R is different from H; `m takes the value 3.